Cabot (NYSE:CBT) Price Target Cut to $80.00 by Analysts at UBS Group

Cabot (NYSE:CBT) had its price objective lowered by UBS Group from $86.00 to $80.00 in a research report issued on Wednesday, Benzinga reports. The brokerage presently has a “neutral” rating on the specialty chemicals company’s stock. UBS Group‘s price target indicates a potential upside of 6.41% from the company’s current price.

Other equities research analysts also recently issued research reports about the stock. Weiss Ratings restated a “hold (c)” rating on shares of Cabot in a research report on Friday, August 21st. Truist Financial dropped their target price on Cabot from $100.00 to $95.00 and set a “buy” rating on the stock in a research report on Wednesday. JPMorgan Chase & Co. increased their target price on Cabot from $70.00 to $78.00 and gave the stock an “underweight” rating in a research note on Friday, August 7th. Finally, Wall Street Zen raised Cabot from a “hold” rating to a “buy” rating in a report on Sunday, October 11th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $85.60.

Cabot Stock Performance

NYSE:CBT traded up $3.18 during midday trading on Wednesday, reaching $75.18. The stock had a trading volume of 548,996 shares, compared to its average volume of 457,183. The firm has a fifty day simple moving average of $77.55 and a two-hundred day simple moving average of $79.52. Cabot has a 12-month low of $58.33 and a 12-month high of $94.53. The company has a quick ratio of 0.97, a current ratio of 1.47 and a debt-to-equity ratio of 0.48. The stock has a market cap of $3.88 billion, a P/E ratio of 18.75, a P/E/G ratio of 8.91 and a beta of 0.83.

Cabot (NYSE:CBT) last announced its quarterly earnings data on Monday, November 2nd. The specialty chemicals company reported $1.61 EPS for the quarter, topping analysts’ consensus estimates of $1.55 by $0.06. Cabot had a net margin of 5.69% and a return on equity of 19.79%. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $927.29 million. During the same quarter in the prior year, the firm earned $1.70 EPS. Cabot’s quarterly revenue was up 12.2% on a year-over-year basis. On average, equities analysts expect that Cabot will post 7.08 EPS for the current year.

Insiders Place Their Bets

In other Cabot news, CEO Sean Keohane sold 134,895 shares of the stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $85.00, for a total value of $11,466,075.00. Following the completion of the transaction, the chief executive officer directly owned 404,134 shares of the company’s stock, valued at approximately $34,351,390. This trade represents a 25.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold 229,597 shares of company stock worth $19,646,746 in the last quarter. Corporate insiders own 3.08% of the company’s stock.

Hedge Funds Weigh In On Cabot

Several hedge funds have recently bought and sold shares of CBT. BlackRock Inc. acquired a new stake in shares of Cabot during the second quarter valued at $633,302,000. Bank of America Corp DE acquired a new position in Cabot in the 2nd quarter valued at about $150,772,000. Bank of New York Mellon Corp acquired a new position in Cabot in the 2nd quarter valued at about $57,445,000. William Blair Investment Management LLC acquired a new position in Cabot in the 2nd quarter valued at about $16,809,000. Finally, State Street Corp lifted its holdings in Cabot by 6.8% in the 2nd quarter. State Street Corp now owns 2,165,434 shares of the specialty chemicals company’s stock valued at $196,665,000 after purchasing an additional 138,098 shares in the last quarter. 93.18% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Cabot

Here are the key news stories impacting Cabot this week:

• Positive Sentiment: Fiscal Q4 adjusted EPS was $1.61, above the $1.55 consensus, while revenue of $1.01 billion topped estimates of about $927 million. The earnings beat provides a near-term positive, although EPS was below $1.70 a year earlier. Cabot beats Q4 earnings and revenue estimates
• Neutral Sentiment: Truist lowered its price target to $95 from $100 but kept a Buy rating, while UBS cut its target to $80 from $86 and maintained Neutral. The mixed views offer support from Truist’s rating but underscore more cautious target expectations. UBS adjusts Cabot price target
• Negative Sentiment: Cabot forecast fiscal 2027 adjusted EPS of $6.15–$6.75, below the analyst consensus of $7.03. The outlook miss could weigh on expectations despite the latest-quarter beat. Cabot forecasts fiscal 2027 adjusted EPS
• Negative Sentiment: Coverage also cited weaker margins as a reason the stock fell following the earnings release. This suggests profitability concerns are offsetting the stronger-than-expected sales and EPS. Cabot falls despite beating estimates on weaker margins

Cabot Company Profile

Cabot Corporation (NYSE: CBT) is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. The company develops and manufactures materials used to improve the performance, durability, conductivity, color and purity of products across a range of industries.

Cabot’s products include carbon black used in tires, rubber goods, coatings, plastics and printing inks; specialty carbons and conductive materials for batteries and other applications; and specialty compounds and masterbatches.